Loading…
Moleculin Biotech, Inc. is projected to rise to $3.10 by 2027, a +36% move from its current price of $2.28. MBRX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.15 | $2.28 | $2.42 | +0.01% |
| Jul 14 | $2.09 | $2.28 | $2.48 | +0.01% |
| Jul 15 | $2.05 | $2.28 | $2.53 | +0.02% |
| Jul 16 | $2.02 | $2.28 | $2.57 | +0.03% |
| Jul 17 | $1.99 | $2.28 | $2.61 | +0.03% |
| Jul 18 | $1.97 | $2.28 | $2.64 | +0.04% |
| Jul 19 | $1.95 | $2.28 | $2.67 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.95 | $2.28 | $2.67 | +0.05% |
| Week 2 | $1.82 | $2.28 | $2.86 | +0.10% |
| Week 3 | $1.73 | $2.28 | $3.01 | +0.14% |
| Week 4 | $1.66 | $2.28 | $3.14 | +0.19% |
| Week 5 | $1.60 | $2.29 | $3.26 | +0.24% |
| Week 6 | $1.55 | $2.29 | $3.38 | +0.29% |
| Week 7 | $1.50 | $2.29 | $3.49 | +0.34% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Moleculin Biotech, Inc. is a late-stage pharmaceutical development company focused on therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas.
MBRX operates in the Healthcare sector. The stock is currently priced at $2.40 per share, with a market cap of $16.96M and a rank of 4896. The near-term price outlook is reflected in the year-by-year forecast, with the 2026 average price at $2.40 and a 2026 range of $1.96 to $3.51, indicating a neutral stance for that year.
The forecast progresses with a bullish tilt in 2027 (avg $3.26) and continues to show upside potential in subsequent years. Across the horizon, the model projects higher averages and larger upside in later years, including 2040 and 2050.
A major floor 37.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 56.6% above — a clean break opens room to run.
A major ceiling 75.4% above — clearing it would confirm fresh momentum.
Key MBRX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MBRX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.36 | Sell | $2.41 | Sell |
| MA 10 | $2.68 | Sell | $2.55 | Sell |
| MA 20 | $2.75 | Sell | $2.63 | Sell |
| MA 50 | $2.57 | Sell | $2.65 | Sell |
| MA 100 | $2.50 | Sell | $3.24 | Sell |
| MA 200 | $5.22 | Sell | $7.45 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.06 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -132.94 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.09 | Sell |
| ROC (12) | -17.09 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.24 | Buy |
| Awesome (5,34) | -0.29 | Sell |
| Ultimate (7,14,28) | 26.81 | Buy |
| Momentum (10) | -0.71 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 2.23 | Buy |
| ADX (14) | 16.13 | Neutral |
| ATR (14) | 0.15 | Info |
The 30-day technical picture is bearish, with RSI14 at 40. The 50-day simple moving average is $2.58 and the 200-day simple moving average is $5.37. Near-term support is at $2.39 and resistance at $3.57. The 30-day trading range runs from $1.56 to $3.70.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.96 | $2.28 | $3.29 | 0% | Neutral | |
| $2.25 | $3.10 | $4.61 | +36% | Bullish | |
| $1.84 | $2.70 | $4.29 | +18% | Neutral | |
| $1.69 | $2.61 | $4.36 | +15% | Neutral | |
| $1.49 | $2.41 | $4.19 | +6% | Neutral | |
| $1.41 | $2.39 | $4.30 | +5% | Neutral | |
| $1.72 | $3.03 | $5.62 | +33% | Bullish | |
| $1.91 | $3.50 | $6.66 | +53% | Bullish | |
| $1.94 | $3.71 | $7.24 | +63% | Bullish | |
| $1.72 | $3.42 | $6.84 | +50% | Bullish | |
| $2.20 | $4.90 | $10.75 | +115% | Bullish | |
| $3.60 | $7.99 | $18.38 | +250% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.96 | $2.28 | $2.71 | +0.00% |
| August 2026 | $1.76 | $2.14 | $2.70 | -6.28% |
| September 2026 | $1.87 | $2.29 | $2.96 | +7.37% |
| October 2026 | $1.94 | $2.41 | $3.16 | +5.13% |
| November 2026 | $1.87 | $2.35 | $3.13 | -2.47% |
| December 2026 | $1.92 | $2.44 | $3.29 | +3.68% |
Click any year to see its month-by-month MBRX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect MBRX to range from $1.96 to $3.29 through 2026. The $2.28 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The MBRX price prediction for 2027 points to an average of $3.10 (low $2.25, high $4.61) — a potential gain of +36% on today's $2.28. Buyers look set to stay in control over this stretch.
In 2028, MBRX is projected to trade between $1.84 and $4.29, averaging $2.70 — a potential gain of +18% from today's $2.28. That is -13% versus the projected 2027 average. Price action looks broadly range-bound.
Moleculin Biotech, Inc.'s 2029 outlook centres on $2.61, within a $1.69 to $4.36 range. That is -3% versus the projected 2028 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, MBRX could reach as high as $4.19, with a base case around $2.41 and support toward $1.49 — roughly +6% from $2.28. Price action looks broadly range-bound.
Expect MBRX to range from $1.41 to $4.30 through 2031. The $2.39 average target implies a +5% move from current prices. That is -1% versus the projected 2030 average. A consolidation phase looks the most probable path here.
The MBRX price prediction for 2032 points to an average of $3.03 (low $1.72, high $5.62) — a potential gain of +33% on today's $2.28. Momentum favours further upside here.
In 2033, MBRX is projected to trade between $1.91 and $6.66, averaging $3.50 — a potential gain of +53% from today's $2.28. That is up +15% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Moleculin Biotech, Inc.'s 2034 outlook centres on $3.71, within a $1.94 to $7.24 range. That is up +6% on the projected 2033 average. That marks a +63% change versus current levels. Momentum favours further upside here.
By 2035, MBRX could reach as high as $6.84, with a base case around $3.42 and support toward $1.72 — roughly +50% from $2.28. Buyers look set to stay in control over this stretch.
Expect MBRX to range from $2.20 to $10.75 through 2040. The $4.90 average target implies a +115% move from current prices. That is up +43% on the projected 2035 average. Momentum favours further upside here.
The MBRX price prediction for 2050 points to an average of $7.99 (low $3.60, high $18.38) — a potential gain of +250% on today's $2.28. Buyers look set to stay in control over this stretch.
Investing $1,000 in MBRX today (≈ 438.596491 MBRX) could be worth
$3,504.91
+$2,504.91 (+250%) by 2050 · US Dollar
Based on the average projected MBRX price of $7.99 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MBRXwould be worth at today's price.
$1,000 invested in MBRX on Jul 10, 2025 (≈ 74.906365 MBRX) would be worth
$170.79
-$829.21 (-82.9%) today · 0.17× · US Dollar
Based on a MBRX entry price of $13.35 vs. today's $2.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.64 | $863.64 | -13.6% |
| 1 month ago | $2.5 | $912 | -8.8% |
| 3 months ago | $2.62 | $870.23 | -13.0% |
| 6 months ago | $4.05 | $562.96 | -43.7% |
| 1 year ago | $13.35 | $170.79 | -82.9% |
| All time (5.0y) ago | $1,335 | $1.71 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MBRX forecast.
Our base-case forecast reaches $4.60 around 2040.
Implied market cap at $4.60: $32.5M
The multi-year forecast shows a neutral stance for 2026 with an average of $2.40, followed by a bullish shift in 2027 with an average of $3.26 and a 35.9% ROI. The sequence continues through 2035 with a sustained bullish sentiment and rising averages, including 2032 at $3.25, 2033 at $3.71, 2034 at $3.89, and 2035 at $3.65, each with positive ROI figures. By 2040, the forecast envisions an average price of $5.14 and a max of $11.29, with a 114.3% ROI and bullish sentiment.
The frontier year 2050 shows an average of $8.64, a max of $19.88, and a 260.1% ROI, maintaining a bullish outlook. These figures are estimates and not guarantees; outcomes depend on factors affecting the company and market conditions.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $1.58, an average of $2.55, and a max of $4.43, with a 6.4% ROI and a neutral sentiment.
The forecast presents a mix of neutral and bullish periods. 2026 is neutral, 2027 is bullish with a 35.9% ROI, and later years such as 2040 (114.3% ROI) and 2050 (260.1% ROI) remain bullish, though these are estimates and not guarantees.
Yes. The 2040 maximum is $11.29 and the 2050 maximum is $19.88, according to the forecast.
The current price is $2.40 and the market cap is $16.96M.
For 2027, the forecast shows an average of $3.26, a minimum of $2.36, a maximum of $4.87, and a 35.9% ROI with a bullish sentiment.
Moleculin Biotech, Inc. Community Discussion
0Share your Moleculin Biotech, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.